President Trump’s hospitalization for COVID-19 has shed the spotlight on the most important aspect in the treatment of the coronavirus – monoclonal antibodies. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases (NIAID), is focused on looking at antivirals that have treated other infectious diseases like HIV to treat COVID-19. Two companies at the forefront of HIV therapeutics are ENZC and BioClonetics, which are set to merge.
In this video, Dr. Fauci lays out the importance of monoclonal antibodies in the treatment of COVID-19.
In analyzing the treatment of President Trump, the Doctors at Walter Reed Medical Center threw everything, but the kitchen sink at the coronavirus. On 2 October, the White House announced President Donald Trump received an experimental antibody treatment after a test revealed he’s infected with SARS-CoV-2. Later, the president’s medical team confirmed he had started a course of remdesivir, an antiviral drug shown to modestly help hospitalized COVID-19 patients. Two days later, on 4 October, the team revealed Trump had been given a steroid normally reserved for severe COVID-19 cases.
The statement released on 2 October by the president’s physician said that in addition to the antibodies, Trump “has been taking zinc, vitamin D, famotidine, melatonin and a daily aspirin.”
What people are failing to realize is that it is uncertain if the treatment(s) given to President Trump will work, and if they do, which one (s) worked. This is why we don’t have a vaccine or an approved treatment from the FDA yet. More testing and funding is needed.
The Importance Of HIV Research
Dr. Fauci is well-known for his contributions to HIV research. He understands the science and the disease perhaps as much an anyone. One company at the heart of HIV research and one which Dr. Fauci is familiar with is BioClonetics Immunotherapeutics, a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for name infectious diseases including the Coronavirus.
Because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, BioClonetics has been asked by the National Science Foundation (NSF) to submit a funding application for the development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health (NIH).
In addition to the antibody treatment, President Trump was given famotidine. Famotidine has been suggested to be a treatment for COVID-19, but it’s also a popular heartburn remedy, sold widely under the name Pepcid.
This is where ENZC comes in to play. Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
The Perfect Merger With ENZC
The reason that the merger between ENZC and BioClonetics makes perfect sense is that BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics’ flagship compound ITV-1, a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.
IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from major neurological, gastrointestinal, and hematological side effects seen in the antiretrovirals in use today. IPF has been shown to not be subject to viral resistance and is cost-effective. Charles Cotropia, CEO of BioClonetics said:
“Our proprietary methodology may also be applied to produce monoclonal antibodies against other infectious diseases and the invitation by the National Science Foundation (NSF) to apply for funding to further BioClonetics efforts to develop anti-SARS-Cov-2 monoclonal antibodies using our proprietary technology is an exciting development for BioClonetics. We have previously produced monoclonal antibodies against HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. We look forward to discovering how ENZC’s ITV-1 treatment can be used with our monoclonal antibody platform to synergistically improve our such antibodies for treating HIV.”
The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.
Thereafter, additional PBMC based in-vitro neutralization studies will be conducted with the BioClonetics Clone 3 recombinant antibodies in combination with the Enzolytics ITV-1 peptide. Based on the results, the best combination will be tested in primate studies at the California National Primate Research Center University of California, Davis, California.
The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as CEO of the merged entity and Harry Zhabilov and Joseph Cotropia, MD, being appointed as co-CSO. Gaurav Chandra, MD, will serve as COO of the merged entity.
ENZC Bottom Line
The ENZC and BioClonetics merger is a game-changer for HIV/COVID-19 treatment. By combining the therapeutics produced by both companies, we believe an effective treatment will finally be available. The next steps we are watching for are 1. the merger closing and 2. NIH funding. We get both and shares of ENZC will go parabolic.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in OTCMKTS:ENZC, or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.